LL Lucky Games AB (”LL Lucky Games" eller "Bolaget”) har presenterat sin Q3-rapport, varpå vi fortsa...
Redeye comments on Zordix Q3-results which came in lower than our forecast driven by lower revenue w...
Q3 ARR of DKK 65m vs. ABGSCe at DKK 67m Recently adjusted FY’22 guidance reiterated Only minor downw...
Better sales as US grew 144% on Catalyst success Underlying estimates relatively unchanged Fair valu...
Redeye will make slight forecast adjustments following Penneo’s Q3 2022 report.
Sales of SEK 1,354m, +12% vs ABGSCe EBITA of SEK 108m, +18% vs ABGSCe We expect cons.
Sales -4% vs ABGSCe Adj. EBITDA +11% vs ABGSCe We expect cons.
Genetic Analysis, ett diagnostikbolag inriktat mot mikrobiota, vars försäljning börjat öka men från ...
Redeye leaves a short comment on Pila Pharma following the outcome of its rights issue which raised ...
EBIT margin strengthened y-o-y in contrast to H1 Positive revisions, ‘23e EBIT up ~4% Generic has no...
Redeye lowers its valuation of QleanAir following a soft Q3’22 report.
Sammantaget var rapporten positiv i stora drag. Katalysen ökade portföljvärdet med cirka sju procent...
Hög bokning/försäljningsgrad Aros Bostad rapporterade rörelseintäkter enligt IFRS på 11,2 mkr i Q3’2...
Redeye comments on Inhalation Sciences’ Q3 2022 report.
CirChem har idag 22 november publicerat bolagets delårsrapport för årets tredje kvartal.
Redeye briefly comments on Acarix's rights issue. We pause our coverage.
Arctic Blue Beverages publicerade den 21 november 2022 bolagets delårsrapport för det tredje kvartal...
Redeye provides a brief comment on the directed share issue, providing OXE Marine with SEK70m.
Avtagande kostnader i Q3 I rapporten för det tredje kvartalet upprepades att Apealea lanserats i Tys...
Lowest production levels since 2018 but robust indicators that workover is completed At 2 389 BOEPD,...
